239 related articles for article (PubMed ID: 9990650)
21. A comparison of the beta1-selectivity of three beta1-selective beta-blockers.
Nuttall SL; Routledge HC; Kendall MJ
J Clin Pharm Ther; 2003 Jun; 28(3):179-86. PubMed ID: 12795776
[TBL] [Abstract][Full Text] [Related]
22. Evolving mechanisms of action of beta blockers: focus on nebivolol.
Mason RP; Giles TD; Sowers JR
J Cardiovasc Pharmacol; 2009 Aug; 54(2):123-8. PubMed ID: 19528811
[TBL] [Abstract][Full Text] [Related]
23. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade.
Bakris G
J Cardiovasc Pharmacol; 2009 May; 53(5):379-87. PubMed ID: 19454898
[TBL] [Abstract][Full Text] [Related]
24. Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol.
Fang Y; Nicol L; Harouki N; Monteil C; Wecker D; Debunne M; Bauer F; Lallemand F; Richard V; Thuillez C; Mulder P
J Mol Cell Cardiol; 2011 Aug; 51(2):168-76. PubMed ID: 21640121
[TBL] [Abstract][Full Text] [Related]
25. Influence of nebivolol on the cardiovascular hemodynamics during postural changes and isometric exercise.
Duprez D; Lefebvre R; De Backer T; De Sutter P; Trouerbach J; Clement DL
Cardiovasc Drugs Ther; 1991 Aug; 5(4):709-17. PubMed ID: 1679662
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
Flather MD; Shibata MC; Coats AJ; Van Veldhuisen DJ; Parkhomenko A; Borbola J; Cohen-Solal A; Dumitrascu D; Ferrari R; Lechat P; Soler-Soler J; Tavazzi L; Spinarova L; Toman J; Böhm M; Anker SD; Thompson SG; Poole-Wilson PA;
Eur Heart J; 2005 Feb; 26(3):215-25. PubMed ID: 15642700
[TBL] [Abstract][Full Text] [Related]
27. Administration of nebivolol after coronary artery bypass in patients with altered left ventricular function.
Goldstein M; Vincent JL; De Smet JM; Barvais L; Van Nueten L; Scheijgrond H; d'Hollander A; Leclerc JL; Kahn RJ
J Cardiovasc Pharmacol; 1993 Aug; 22(2):253-8. PubMed ID: 7692166
[TBL] [Abstract][Full Text] [Related]
28. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
von Fallois J; Faülhaber HD
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490
[TBL] [Abstract][Full Text] [Related]
29. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
van Veldhuisen DJ; Cohen-Solal A; Böhm M; Anker SD; Babalis D; Roughton M; Coats AJ; Poole-Wilson PA; Flather MD;
J Am Coll Cardiol; 2009 Jun; 53(23):2150-8. PubMed ID: 19497441
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol.
Kuroedov A; Cosentino F; Lüscher TF
Cardiovasc Drug Rev; 2004; 22(3):155-68. PubMed ID: 15492765
[TBL] [Abstract][Full Text] [Related]
31. Nebivolol in the management of essential hypertension: a review.
McNeely W; Goa KL
Drugs; 1999 Apr; 57(4):633-51. PubMed ID: 10235696
[TBL] [Abstract][Full Text] [Related]
32. Nebivolol increases arterial distensibility in vivo.
McEniery CM; Schmitt M; Qasem A; Webb DJ; Avolio AP; Wilkinson IB; Cockcroft JR
Hypertension; 2004 Sep; 44(3):305-10. PubMed ID: 15262912
[TBL] [Abstract][Full Text] [Related]
33. Nebivolol is devoid of intrinsic sympathomimetic activity.
Janssens WJ; Van de Water A; Xhonneux R; Reneman RS; Van Nueten JM; Janssen PA
Eur J Pharmacol; 1989 Jan; 159(1):89-95. PubMed ID: 2565239
[TBL] [Abstract][Full Text] [Related]
34. Nebivolol: a review of its use in the management of hypertension and chronic heart failure.
Moen MD; Wagstaff AJ
Drugs; 2006; 66(10):1389-409; discussion 1410. PubMed ID: 16903772
[TBL] [Abstract][Full Text] [Related]
35. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits.
de Nigris F; Mancini FP; Balestrieri ML; Byrns R; Fiorito C; Williams-Ignarro S; Palagiano A; Crimi E; Ignarro LJ; Napoli C
Nitric Oxide; 2008 Aug; 19(1):57-63. PubMed ID: 18435936
[TBL] [Abstract][Full Text] [Related]
37. Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats.
Sacco G; Evangelista S; Criscuoli M; Goso C; Bigioni M; Binaschi M; Manzini S; Maggi CA
Eur J Pharmacol; 2005 Mar; 511(2-3):167-74. PubMed ID: 15792785
[TBL] [Abstract][Full Text] [Related]
38. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
Gupta S; Wright HM
Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
[TBL] [Abstract][Full Text] [Related]
39. Nebivolol: a review of its clinical and pharmacological characteristics.
Gielen W; Cleophas TJ; Agrawal R
Int J Clin Pharmacol Ther; 2006 Aug; 44(8):344-57. PubMed ID: 16961165
[TBL] [Abstract][Full Text] [Related]
40. Nebivolol: third-generation beta-blockade.
de Boer RA; Voors AA; van Veldhuisen DJ
Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
